Clinical Trial Update: Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing whether the meningococcal B vaccine 4CMenB can induce mucosal immune responses against Neisseria gonorrhoeae; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• 4CMenB (Bexsero) (Meningococcal B vaccine, four-component (4CMenB))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gonorrhoea | Phase 2 | Status: COMPLETED | Results posted: 2024-11-05